心力衰竭中的铁缺乏与达格列净的作用:DAPA-HF研究结果
在DAPA-HF试验中,基线可评估铁状态的3009例患者里43.7%存在铁缺乏,铁缺乏者主要结局发生率更高(16.6 vs 10.4/100人年,P<0.0001)。达格列净对主要结局的获益在铁缺乏与铁充足患者中一致(HR 0.74 vs 0.81,交互P=0.59)。达格列净降低了转铁蛋白饱和度、铁蛋白和铁调素,升高了总铁结合力和可溶性转铁蛋白受体。
要点
- DAPA-HF人群中铁缺乏常见,占可评估患者的43.7%,且与更差结局相关。
- 达格列净改善主要结局的效应不受基线铁状态影响,交互P=0.59。
- 达格列净可能增加铁利用,表现为转铁蛋白饱和度下降、可溶性转铁蛋白受体升高。
核心结论
- 铁缺乏在DAPA-HF中常见且与更差结局相关,达格列净似乎增加铁利用但改善结局,无论基线铁状态如何。
研究设计与样本
- DAPA-HF试验随机4744例患者,其中3009例有基线铁蛋白和转铁蛋白饱和度测量,用于本分析。
主要发现
- 铁缺乏定义为铁蛋白<100 ng/mL或转铁蛋白饱和度<20%且铁蛋白100-299 ng/mL,3009例中1314例(43.7%)存在铁缺乏。
- 铁缺乏患者主要结局发生率为16.6/100人年,高于无铁缺乏者的10.4/100人年(P<0.0001)。
- 达格列净对主要结局的效应在铁缺乏与铁充足患者中一致(HR 0.74 [95%CI 0.58-0.92] vs 0.81 [95%CI 0.63-1.03],交互P=0.59)。
- 心血管死亡、心衰住院和全因死亡率的结果相似。
- 与安慰剂相比,达格列净降低转铁蛋白饱和度、铁蛋白和铁调素,升高总铁结合力和可溶性转铁蛋白受体。
关键数值与推荐
- 铁缺乏定义:铁蛋白<100 ng/mL,或转铁蛋白饱和度<20%且铁蛋白100-299 ng/mL。
- 主要结局为心衰恶化(住院或需静脉治疗的紧急就诊)或心血管死亡的复合终点。
临床怎么用
- 达格列净改善心衰结局的疗效不受基线铁状态影响,铁缺乏患者同样获益。
- 达格列净治疗中应关注铁代谢指标变化,但其铁利用增加与结局改善的关系需进一步研究。
局限性
- 仅3009/4744例患者有基线铁蛋白和转铁蛋白饱和度测量,可能存在选择偏倚。
- 铁代谢标志物仅在基线和12个月测量,缺乏更长期动态数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Iron deficiency is common in heart failure and associated with worse outcomes. We examined the prevalence and consequences of iron deficiency in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) and the effect of dapagliflozin on markers of iron metabolism. We also analyzed the effect of dapagliflozin on outcomes, according to iron status at baseline. METHODS: Iron deficiency was defined as a ferritin level <100 ng/mL or a transferrin saturation <20% and a ferritin level 100 to 299 ng/mL. Additional biomarkers of iron metabolism, including soluble transferrin receptor, erythropoietin, and hepcidin were measured at baseline and 12 months after randomization. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death. RESULTS: Of the 4744 patients randomized in DAPA-HF, 3009 had ferritin and transferrin saturation measurements available at baseline, and 1314 of these participants (43.7%) were iron deficient. The rate of the primary outcome was higher in patients with iron deficiency (16.6 per 100 person-years) compared with those without (10.4 per 100 person-years; P<0.0001). The effect of dapagliflozin on the primary outcome was consistent in iron-deficient compared with iron-replete patients (hazard ratio, 0.74 [95% CI, 0.58-0.92] versus 0.81 [95% CI, 0.63-1.03]; P-interaction=0.59). Similar findings were observed for cardiovascular death, heart failure hospitalization, and all-cause mortality. Transferrin saturation, ferritin, and hepcidin were reduced and total iron-binding capacity and soluble transferrin receptor increased with dapagliflozin compared with placebo. CONCLUSIONS: Iron deficiency was common in DAPA-HF and associated with worse outcomes. Dapagliflozin appeared to increase iron use but improved outcomes, irrespective of iron status at baseline. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03036124.
引用
- Docherty, Welsh, Verma, et al. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Circulation. 2022. PMID: 35971840. doi:10.1161/CIRCULATIONAHA.122.060511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。